ストックスクリーナーアプリを入手
0.4992
2.82%
-0.0145
アフターアワーズ：
.50
0.0008
+0.16%
前日終値:
$0.5137
開ける：
$0.5
24時間の取引高:
94,762
Relative Volume:
0.15
時価総額：
$16.68M
収益：
-
当期純損益:
$-19.73M
株価収益率:
-0.2407
EPS:
-2.0742
ネットキャッシュフロー:
$-16.94M
1週間 パフォーマンス:
-4.68%
1か月 パフォーマンス:
-10.86%
6か月 パフォーマンス:
-36.11%
1年 パフォーマンス:
-29.68%
1日の値動き範囲:
$0.4852
$0.5097
1週間の範囲:
$0.4852
$0.5298
52週間の値動き範囲:
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
名前
Pasithea Therapeutics Corp
セクター
電話
(702) 514-4174
住所
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.4992 | 16.68M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pasithea Therapeutics Corp (KTTA) 最新ニュース
Pasithea Therapeutics Announces Nasdaq Warrant Expiration - TipRanks
Pasithea Therapeutics Corp.Common Stock (Nasdaq:KTTA) Price Chart - The Chronicle-Journal
Pasithea Therapeutics warrants to expire Sept. 17, 2026; delisting and deregistration planned - TradingView
Pasithea Therapeutics (NASDAQ: KTTA) says KTTAW warrants will lose all value - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) withdraws its warrants from Nasdaq listing - Stock Titan
Pasithea Therapeutics Slides As Insider Purchases Lose Another US$48k - simplywall.st
Pasithea Therapeutics to Present Initial PAS-004 Clinical Data in Oral and Poster Sessions at 2026 European Neurofibromatosis Conference - quiverquant.com
A nerve-tumor drug trial’s first clinical data will be presented in Vienna this November - Stock Titan
Pasithea Therapeutics Corp. Warrant (KTTAW) Peer Comparison – Compare with Others - Value Research
Pasithea Therapeutics Shareholders Approve Reverse Stock Split - TipRanks
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - Yahoo! Finance Canada
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView
Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance - The Globe and Mail
Pasithea Therapeutics Received Notice of Noncompliance - TradingView
Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting - Stock Titan
Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest ReadingLow Growth Earnings - vinanet.vn
Pasithea Therapeutics Company Profile & Introduction - Moomoo
Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView
KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView
Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan
KTTA Q1 2026 Earnings: Narrower-than-Expected Loss of $0.12 Per Share Highlights Cost ControlProduct Revenue Analysis - dars.gov.et
KTTA Q1 2026 Earnings: Deep Loss Narrowing Beats Estimates by Wide MarginEarnings Analysis - careplusvn.com
Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView
Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics (KTTA) Jumps 14% as Price Approaches Key ResistanceFibonacci Time Zone - vinanet.vn
Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan
Pasithea Therapeutics Corp. Revenue Breakdown – BOATS:KTTAW - TradingView
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48TRIN Signal - vinanet.vn
Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net
Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan
Pasithea Therapeutics Corp (KTTA) Cash Flow - TradingKey
Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KTTA|Pasithea Therapeutics Corp|Price:0.452|Chg%:-0.003 - TradingKey
Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp. Revenue Breakdown – NASDAQ:KTTA - TradingView
KTTA|Pasithea Therapeutics Corp|Price:0.455|Chg%:-0.025 - TradingKey
Pasithea Therapeutics (KTTA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise Amid Revenue AbsenceAnnual Report - po-news-eg.net
KTTA Q1 2026 Earnings: Significant EPS Beat Despite No Revenue; Stock Gains 4.4%Post-Earnings Reaction - dars.gov.et
Pasithea Therapeutics Corp. (KTTA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history - Yahoo Finance UK
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology Congress 2026 - Investing News Network
Pasithea Therapeutics (KTTA) Registration filing Summary - Quartr
Pasithea Therapeutics (KTTA) Proxy filing Summary - Quartr
Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative
Pasithea Therapeutics Corp (KTTA) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):